- 3 Jun 2020 US Patent Trial and Appeal Board rejects fifth request by Regeneron for invalidation of Kymab's US patents
- 6 Dec 2019 Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition
- 13 Nov 2019 Kymab to Present Update on Lead Immunocytokine Program KY1043 at Two European Scientific Meetings in November 2019
- 8 Nov 2019 Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting
- 3 Oct 2019 Kymab Announces Presentation on KY1049 at the European Congress on Thrombosis and Haemostasis
- 27 Sep 2019 Kymab outlines positive new findings for its KY1044 Anti-ICOS program at the CICON 2019 Annual Meeting
- 24 Jun 2019 Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies
- 13 Jun 2019 Kymab Announces Presentations at the 24th EHA Annual Congress
- 1 Jun 2019 Kymab Poster on Adaptive Phase 1/2 Clinical Trial for KY1044 anti-ICOS Program at 2019 ASCO Meeting
- 18 Apr 2018 Kymab presents data on two of its immuno-oncology antibodies, providing further evidence of the strength of its franchise
We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Kymab wins Supreme Court case against Regeneron
Landmark UK Supreme Court decision invalidates Regeneron Patent claims
Read article
Featured article: Kymab presents two e-posters at the American Association for Cancer Research Virtual Annual Meeting
Cambridge, UK; 22 June 2020: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced th...
Read article